Noah Capurso, MD, MHS. Assistant Medical Director, Addiction Services Division, Connecticut Valley Hospital; Associate Clinical Professor of Psychiatry, Yale University; Editor-in-Chief, The Carlat Addiction Treatment Report.
Dr. Capurso has no financial relationships with companies related to this material.
In May, the CDC reported a remarkable improvement in drug overdose deaths across the United States. The number fell from 110,037 in 2023 to 80,391 in 2024—a nearly 27% reduction in a single year and the largest annual decrease since the overdose epidemic began over three decades ago. Nearly all regions saw improvements, with some of the hardest-hit areas—such as West Virginia, Ohio, and Washington, DC—experiencing declines of 35% or more. Researchers are still working to understand the causes of this progress, but likely contributors include expanded access to buprenorphine and methadone, widespread naloxone distribution, including over-the-counter availability, and growing adoption of harm reduction strategies. A shrinking supply of fentanyl and a shift toward lower potency in the illicit drug market may also have played a role. While this is encouraging news, overdose death rates remain high and are still above pre-pandemic levels. So we need to keep the momentum going: Continue to deliver evidence-based addiction care, embrace harm reduction, and ensure every patient has access to naloxone.
—Noah Capurso, MD, MHS
noah.capurso@yale.edu
Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.
© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.